Pfizer Commended For Leadership In Addressing Climate Change

Pfizer Inc.Pfizer Inc. (NYSE: PFE) has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. For the fourth consecutive year, CDP named Pfizer to its Carbon Disclosure Leadership Index, which highlights the company's climate change disclosure practices. Pfizer was ranked highest among the S&P 500 health care companies on the index - the third consecutive year that Pfizer made the S&P list - and ranked fourth on CDP's Global 500 health care companies list.

"Pfizer's commitment to reducing our impact on the environment fits perfectly with our mission to address health needs worldwide," said Nat Ricciardi, president of Pfizer Global Manufacturing and the company's leadership sponsor of its Environmental Sustainability Program. "I'm especially proud of the innovative ideas and hard work by our employees to achieve these reductions and contribute to Pfizer's sustainable practices."

According to Mr. Ricciardi, Pfizer exceeded its initial goal to reduce greenhouse gas emissions by achieving a 43 percent reduction relative to revenue between 2000 and 2007. The company's second goal, to be achieved between 2007 and the end of 2012, is to cut greenhouse gases by 20 percent on an absolute basis.

"We've made significant progress on our current goal," said Mr. Ricciardi. "Energy teams at Pfizer facilities around the world completed more than 500 conservation-related projects in 2009, greatly reducing Pfizer's annual energy usage while cutting C02 emissions by 120,000 metric tons."

Examples of Pfizer projects include installation of a biomass boiler at a plant in Freiburg, Germany; start-up of a five megawatt cogeneration unit in Grange Castle, Ireland; installation of high efficiency chiller and "free-cooling" heat exchanger at a commercial facility in Peapack, N.J.; reduced demand on HVAC systems through targeted hours of use and temperature settings at a research site in Sandwich, United Kingdom; and installation of energy-efficient light fixtures, occupancy sensors and timers at Pfizer facilities in Kalamazoo, Mich.

Paul Dickinson, Chief Executive of CDP, said the Carbon Disclosure Leadership Index recognizes companies that demonstrate good internal data management practices for understanding greenhouse gas emissions, including energy use. "Companies that make this index have also demonstrated clear consideration of how climate change is and will impact their business," Mr. Dickinson said. "As companies' understanding of climate change issues grows, they are better placed to take positive action to manage and mitigate its risks."

CDP is a not-for-profit coalition of 534 institutional investors with $64 trillion in assets under management. This index, a key component of CDP's annual S&P 500 Report, highlights the constituent companies within the S&P 500 Index which have displayed the most professional approach to corporate governance in respect of climate change disclosure practices. Companies are scored on their climate change disclosure and high scores indicate good internal data management and understanding of climate change related issues affecting the company.

The S&P 500 Report, including names of companies featured in the Carbon Disclosure Leadership Index, can be found at www.cdproject.net.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]